NanoZymeX Secures CHF 150K for Rare Disease Enzyme Therapies

Basel, Switzerland – A novel approach to enzyme replacement therapy is gaining traction as NanoZymeX, a biotech innovator emerging from Swiss academic research, has secured CHF 150,000 in pre-seed funding from Venture Kick. This capital infusion is earmarked to propel the development of its proprietary lipid nanoparticle platform, designed to enhance the cellular delivery of therapeutic enzymes for debilitating rare genetic disorders.

The company, a spin-out from the University of Zurich and now operating within the University of Basel's Nanopharmaceutical and Regulatory Science Group, is tackling a fundamental hurdle in enzyme replacement therapy: ensuring these vital proteins reach their intended cellular destinations, particularly within lysosomes. Founded by Boris Sevarika and Margarita C. Dinamarca, NanoZymeX's technology bypasses conventional uptake pathways, aiming for more efficient intracellular enzyme activity. This could significantly improve therapeutic outcomes for patients suffering from conditions where specific enzyme deficiencies lead to severe health consequences.

Initial efforts by NanoZymeX are focused on Pompe disease, a lysosomal storage disorder affecting neuromuscular function. The market for Pompe disease treatments already surpasses $2 billion globally, underscoring the significant unmet need and commercial potential. However, the broader applicability of NanoZymeX's reusable delivery system extends to a wide spectrum of other enzyme-driven rare and metabolic diseases, positioning the company for a diversified pipeline. The lysosomal storage disease market alone represents a substantial $9 billion opportunity.

The strategic advantage of NanoZymeX's platform lies in its capital efficiency. By leveraging a core lipid nanoparticle technology across multiple therapeutic targets, the company can develop its pipeline more economically. The business strategy involves advancing lead candidates to early clinical validation before seeking out-licensing agreements with established pharmaceutical partners. This model anticipates revenue generation through upfront payments, milestone achievements, and ongoing royalties, aligning with industry norms for rare disease drug development.

This latest funding from Venture Kick, a prominent Swiss initiative supporting early-stage startups, will be instrumental in refining NanoZymeX's business strategy. The funds will support crucial stakeholder engagement, including structured interviews to validate the therapeutic approach, and bolster connections with key opinion leaders in the enzyme therapy and lysosomal storage disorder fields. The company's selection as a Venture Leaders Biotech 2026 participant further enhances its support network through dedicated mentorship and networking opportunities.

The broader implications for the biotechnology sector are considerable. Innovations like NanoZymeX's platform highlight a growing trend towards sophisticated drug delivery systems that enhance therapeutic efficacy and broaden the reach of treatments for complex diseases. As the pharmaceutical industry continues to invest heavily in rare disease research, companies offering novel delivery mechanisms are well-positioned to capture significant market share and address critical patient needs.